Overall, immunotherapy was adopted pretty rapidly after it was approved for the treatment of several cancers, but smaller and rural oncologic practices were slower on the uptake.
The latest American Cancer Society annual report highlights an increase in late-stage prostate cancer diagnoses, but also a dramatic fall in cervical cancer in young women.
Immunotherapy combinations based on nivolumab entail lower costs for grade 3/4 adverse events than those using pembrolizumab, a finding that could inform treatment decisions.
Multicancer early detection tests are finally a reality and could be a potential game changer because may be able to screen for up to 50 different cancers in asymptomatic individuals with one blood draw.